DISCLAIMER: This page is intended for members of the general public in Singapore only.
The information provided on this site is intended for general information and education for Singapore-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.
Information about the NuvaxovidTM (NVX-CoV2373)
The Health Sciences Authority (HSA) of Singapore has granted full approval for Novavax's prototype COVID-19 vaccine Nuvaxovid™ (NVX-CoV2373) for active immunization to prevent COVID-19 in individuals aged 12 and older. The Singapore Ministry of Health has included Nuvaxovid in the National Vaccination Programme as a protein-based non-mRNA option for COVID-19 prevention.
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Singapore: https://www.hsa.gov.sg/adverse-events.
Tel: +65 8003211411
09:00 - 17:00
Monday - Friday